ClinicaSpace.com
Clinical Research
News & Careers
 
Search the Site
    
 
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   
 News | News By Subject | News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

GlaxoSmithKline (GSK), Shionogi & Co., Ltd. Say HIV Drug Beats Gilead Sciences, Inc. (GILD) Atripla in Test


7/11/2012 6:44:43 AM

An experimental treatment for HIV developed by GlaxoSmithKline Plc (GSK), Pfizer Inc. (PFE) (PFE) and Shionogi & Co. (4507) reduced the virus in more people than Gilead Sciences Inc. (GILD) (GILD)’s Atripla, suggesting it may supplant the world’s best-selling AIDS medicine as the preferred front-line therapy. After 48 weeks of treatment, 88 percent of patients receiving a combination of dolutegravir and two other drugs in a study had undetectable levels of virus in their blood, compared with 81 percent of those getting Atripla, London-based Glaxo and Shionogi of Osaka, Japan, said in a joint statement today. The difference was primarily the result of more patients on Atripla dropping out because of side effects, they said.

Read at BusinessWeek
Read at Reuters
Read at Share Cast
Read at News Release
 
 Read Article at  Related Companies  News Categories
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES